Related references
Note: Only part of the references are listed.Effect of canagliflozin on liver function tests in patients with type 2 diabetes
L. A. Leiter et al.
DIABETES & METABOLISM (2016)
The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome
Nancy E. Aguilar-Olivos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda et al.
PLOS ONE (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes
Tsuyoshi Mashitani et al.
BIOMEDICAL REPORTS (2016)
The Impact of Phlebotomy in Nonalcoholic Fatty Liver Disease: A Prospective, Randomized, Controlled Trial
Leon A. Adams et al.
HEPATOLOGY (2015)
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
Shirong Qiang et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice
Shigeru Nakano et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2015)
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Masanori Yokono et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
Tomoyuki Iwasaki et al.
HEPATO-GASTROENTEROLOGY (2011)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
R. Loomba et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Share Paper
